Connect with us

Subscribe

biotech

€400K fund to fight Parkinson’s

BARCELONA – Molomics Biotech is seeking investment of €400K to fund its fight against Parkinson’s. The company’s investment round via the Capital Cell platform is all about progressing its AI-inspired treatment for the control o fLevodopa Induced Dyskinesia, a ‘movement disorder that can cause a significant physical disability’.

“We have decided to collaborate with Capital Cell to allow anyone in Spain to become a partner of Molomics and support the fight against Parkinson’s, which, if successful, could lead to a lucrative return on investment,” said Jascha Blobel, CEO of Molomics, which is based at Barcelona Science Park.

Discover more about Molomics Biotech’s latest funding round to support innovation that tackles a disease which destroys the lives of millions worldwide.

Newsletter Signup

Staff reporter
Written By

Advertisement

Tiny brain implants target Parkinson’s

technology

Parkinson’s sufferer writes again

technology

Wearables can personalise Parkinson’s treatment

technology

Connect
Newsletter Signup